Literature DB >> 16082538

Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis.

Sergi Mas1, Anna Crescenti, Jose M Vidal-Taboada, Salvador Bergoñon, Fernando Cuevillas, Nuria Laso, Rafael Molina, Antonio Ballesta, Amalia Lafuente.   

Abstract

OBJECTIVE: To conduct a descriptive study on the prevalence of relevant cytochrome P450 2C9 (CYP2C9) polymorphisms--the *2, *3, and 5' flanking region (C-1189T)--in a Spanish population using a new minisequencing fluorescent method through a multiplex single base extension (SBE) analysis.
METHOD: The method simultaneously and accurately genotypes the CYP2C9 polymorphisms studied and is available as a commercial protocol (SNaPshot). Various strategies, including restriction fragment length polymorphism (RFLP) and Taqman, were used to validate the methodology.
RESULTS: The frequencies of alleles CYP2C9*2 (12%) and *3 (6.2%) were similar to those described for other Caucasian populations. The frequency of allele t at the 5' flanking region was 62%, which is close to the percentage reported in Japanese and French populations. The four haplotypes inferred in our samples and their frequencies were consistent with those reported in other studies.
CONCLUSION: Our results confirm previously reported Caucasian frequencies for the CYP2C9*2 and *3 alleles and, for the first time, provide data on the frequency of the CYP2C9 5' flanking region (C-1189T), a recently described polymorphism, in a Spanish population. The SBE technique detects unequivocally the three polymorphisms in a single reaction, which makes it suitable for the analysis of CYP2C9 in the many therapeutic situations in which it is involved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082538     DOI: 10.1007/s00228-005-0977-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  32 in total

1.  Multiplex automated primer extension analysis: simultaneous genotyping of several polymorphisms.

Authors:  N M Makridakis; J K Reichardt
Journal:  Biotechniques       Date:  2001-12       Impact factor: 1.993

2.  NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors.

Authors:  M J Lafuente; X Casterad; M Trias; C Ascaso; R Molina; A Ballesta; S Zheng; J K Wiencke; A Lafuente
Journal:  Carcinogenesis       Date:  2000-10       Impact factor: 4.944

3.  Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse.

Authors:  K Lindblad-Toh; E Winchester; M J Daly; D G Wang; J N Hirschhorn; J P Laviolette; K Ardlie; D E Reich; E Robinson; P Sklar; N Shah; D Thomas; J B Fan; T Gingeras; J Warrington; N Patil; T J Hudson; E S Lander
Journal:  Nat Genet       Date:  2000-04       Impact factor: 38.330

4.  Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.

Authors:  M Shintani; I Ieiri; K Inoue; K Mamiya; H Ninomiya; N Tashiro; S Higuchi; K Otsubo
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

5.  Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.

Authors:  R Brandolese; M G Scordo; E Spina; M Gusella; R Padrini
Journal:  Clin Pharmacol Ther       Date:  2001-10       Impact factor: 6.875

Review 6.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

7.  CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Authors:  Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

8.  The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

Authors:  Pär Hallberg; Julia Karlsson; Lisa Kurland; Lars Lind; Thomas Kahan; Karin Malmqvist; K Peter Ohman; Fredrik Nyström; Håkan Melhus
Journal:  J Hypertens       Date:  2002-10       Impact factor: 4.844

Review 9.  Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.

Authors:  U I Schwarz
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

Review 10.  Biochemistry and molecular biology of the human CYP2C subfamily.

Authors:  J A Goldstein; S M de Morais
Journal:  Pharmacogenetics       Date:  1994-12
View more
  1 in total

1.  Satisfaction survey with DNA cards method to collect genetic samples for pharmacogenetics studies.

Authors:  Jose M Vidal-Taboada; Mercedes Cucala; Sergio Mas Herrero; Amalia Lafuente; Albert Cobos
Journal:  BMC Med Genet       Date:  2006-05-08       Impact factor: 2.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.